In summary, the presence of CD8+FoxP3+PD-1+ cells in advanced NSCLC tissues and their close spatial proximity to tumor cells might be crucial for favorable survival outcomes in patients receiving immunotherapy. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.